Literature DB >> 12821823

Tests for mitochondrial function and DNA: potentials and pitfalls.

Andrea Cossarizza1.   

Abstract

PURPOSE OF REVIEW: In the past few years, mitochondria have been carefully studied to ascertain whether and how in patients affected by HIV antiretroviral therapy is able to alter their functionality and exert a toxic effect on immune cells, as well as on cells present in other districts. RECENT
FINDINGS: A variety of in-vivo and ex-vivo models have been developed to investigate the functionality of mitochondria and DNA during a variety of physiopathological situations, including HIV infection and its treatment. Numerous technologies are available to study at the single-cell or at the single-organelle level a variety of parameters, such as membrane potential, the activity of respiratory chain enzymes, and DNA content or its sequence. As far as in-vitro studies are concerned, a substantial homogeneity of data exists, and several changes in different mitochondrial parameters have been described that depend upon the drug used, the cell model and the parameter investigated. On the other hand, different results have been reported on biological material collected from HIV-positive patients and immediately analysed. Ex-vivo studies showed that changes in mitochondrial DNA content or in the functionality of the organelle exist in some tissues or cells, but not in others.
SUMMARY: One of the possible causes of the discrepancies is the technologies used to investigate mitochondria, and this paper summarizes some of the pros and cons of the main methods used to study mitochondrial function or DNA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12821823     DOI: 10.1097/00001432-200302000-00002

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  6 in total

1.  Peripheral blood mitochondrial DNA copy number as a novel potential biomarker for diabetic nephropathy in type 2 diabetes patients.

Authors:  Ghada Al-Kafaji; Abdulah Aljadaan; Amer Kamal; Moiz Bakhiet
Journal:  Exp Ther Med       Date:  2018-06-15       Impact factor: 2.447

2.  Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.

Authors:  Akihiko Saitoh; Terence Fenton; Carmelita Alvero; Courtney V Fletcher; Stephen A Spector
Journal:  Antimicrob Agents Chemother       Date:  2007-09-24       Impact factor: 5.191

3.  Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy.

Authors:  Grace A McComsey; Minhee Kang; Allison C Ross; Dirk Lebrecht; Elizabeth Livingston; Ann Melvin; Jane Hitti; Susan E Cohn; Ulrich A Walker
Journal:  HIV Clin Trials       Date:  2008 Mar-Apr

4.  Adjusting MtDNA Quantification in Whole Blood for Peripheral Blood Platelet and Leukocyte Counts.

Authors:  Yamilee Hurtado-Roca; Marta Ledesma; Monica Gonzalez-Lazaro; Raquel Moreno-Loshuertos; Patricio Fernandez-Silva; Jose Antonio Enriquez; Martin Laclaustra
Journal:  PLoS One       Date:  2016-10-13       Impact factor: 3.240

5.  Cardiac and mitochondrial function in HIV-uninfected fetuses exposed to antiretroviral treatment.

Authors:  Laura García-Otero; Marta López; Mariona Guitart-Mampel; Constanza Morén; Anna Goncé; Carol Esteve; Laura Salazar; Olga Gómez; Josep María Martínez; Berta Torres; Sergi César; Glòria Garrabou; Fàtima Crispi; Eduard Gratacós
Journal:  PLoS One       Date:  2019-03-04       Impact factor: 3.240

6.  Mitochondrial Toxicogenomics for Antiretroviral Management: HIV Post-exposure Prophylaxis in Uninfected Patients.

Authors:  Maria Bañó; Constanza Morén; Sergio Barroso; Diana Luz Juárez; Mariona Guitart-Mampel; Ingrid González-Casacuberta; Judith Canto-Santos; Ester Lozano; Agathe León; Enric Pedrol; Òscar Miró; Ester Tobías; Josep Mallolas; Jhon F Rojas; Francesc Cardellach; Esteban Martínez; Gloria Garrabou
Journal:  Front Genet       Date:  2020-05-26       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.